Project Grant R43AI197687
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases awarded Datanova Scientific LLC $306,969 on July 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop TRACE-CDI, a digital platform for automated root cause analysis of hospital-acquired Clostridioides difficile infections. The project delivers a scalable, technology-driven system that integrates electronic health records and hospital data to streamline root cause analysis and improve infection...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded $762,758 to the Board of Regents of the University of Nebraska, acting through its University of Nebraska Medical Center division in Omaha, Nebraska, on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient is developing bioengineered 3D bioprinted scaffolds to treat Staphylococcus aureus biofilm infections following craniotomy procedures. The scaffolds employ two delivery...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $159,140 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct molecular epidemiology research on New Delhi metallo-B-lactamase-producing Enterobacterales (NDM-E) infections. The research integrates genotype, phenotype, and patient-level outcomes to develop allele-specific therapeutic guidance for NDM-E treatment. Aim 1 defines the genetic epidemiology of...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $100,228 on November 23, 2026, to develop and evaluate novel biostatistical methods for human microbiome metagenomic data analysis under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds two primary research aims. In Aim 1, the recipient will systematically evaluate widely used methods for analyzing longitudinal microbiome data—specifically mixed-effects models—and develop a simpler...
- The National Institute of Allergy and Infectious Diseases awarded the Board of Trustees of Southern Illinois University $547,292 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid diagnostic system for bacteremia pathogen identification and antimicrobial susceptibility testing. The project integrates immunocapture, microfluidics, and artificial intelligence to detect bacteria directly from blood samples at low concentrations (1–103...
- Federal Grant Award Summary New York University School of Medicine received a $3.21 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 25, 2025, with a completion date of June 30, 2029. The award funds research into real-time detection of Staphylococcus aureus transmission in hospital settings, with particular emphasis on methicillin-resistant S. aureus (MRSA)....
- The National Institute of Allergy and Infectious Diseases awarded Catholic University of America $596,250 on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to prototype a rapid antibiotic susceptibility testing platform using multiplex static gradients. The project aims to develop a microfluidic device that identifies effective antibiotics within 30 minutes for acute bacterial infections such as sepsis, urinary tract infections, and bloodstream...
The National Institute of Allergy and Infectious Diseases awarded Innovative Design Labs Inc. $313,110 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an automated assessment system for sterile procedure training on mannequin simulations. The project will create hardware, sensing technology, and artificial intelligence models to objectively evaluate aseptic and sterile technique training that currently relies on manual, in-person instructor oversight. The system will enable trainees to replay and learn from errors, practice independently, and document competence for certification and credentialing. Phase I specific aims include defining and producing system hardware and sensing capabilities, collecting training datasets and developing AI models with accuracy evaluation, and developing a prototype user interface with stakeholder feedback. Healthcare-associated infections rank among the top 10 leading causes of death in the United States, with tens of thousands of lives lost annually and billions in costs. An estimated 55 to 70 percent of these infections are preventable through proper training in sterile procedures. Current instructor-led assessment approaches are time-consuming, expensive, and subjective; the proposed automated system aims to provide cost-effective objectivity to this training process. Performance takes place in Minneapolis, Minnesota, with a period of performance through July 31, 2027. The award is a Project Grant, the assistance type for competitive research projects supporting individual investigators.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $313.1k | 8/18/26 |